Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
Overall Risk Factors
HAP/ VAP Patient Profile
cIAI Patient Profile
cUTI Patient Profile
"In the face of increasing rates of antimicrobial resistance in complicated urinary tract infections (cUTIs), clinicians need to understand cross-resistance patterns among commonly encountered pathogens." Zilberberg M D, et al (2020)24
*The example described here is not an actual patient, but rather a fictious representation of a scenario for which ZAVICEFTA could be considered.
Patient History: |
|
Symptoms: |
|
Diagnosis: |
|
Suspected Pathogens: |
|
Access dosing guide
View Phase III trial
Abbreviations:
cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; K. pneumoniae, Klebsiella pneumoniae; MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; P. aeruginosa, Pseudomonas aeruginosa; CrCl, creatinine clearance; AMR, Antimicrobial Resistance; CVC central venous catheter; ICU intensive care unit. AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; TOC, test of cure;
Prescribing information
Zavicefta (ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion
The card body Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.
** This is an optional area where footnotes can live.
Professor Francesco G. De Rosa, Prof. of Infectious Diseases (Italy, Professor Philip Montravers, Anaestheisa and Critical Care Medicine (France) and Dr Paula Ramirez, Critical Care Department (Spain) discuss high-risk patients and early treatment of patients with suspected MDR Gram-negative infections in their clinical practice, and their experience using ZAVICEFTA.
** This is an optional area where footnotes can live.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
No
OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?